Abstract
We investigated the influence of the polymorphism D104N of the COL18A1 gene, encoding endostatin, on the occurrence of sporadic breast cancer in 181 patients and 448 controls. The homozygous 104NN polymorphism was found in five patients but was absent in controls (2.8% vs 0.0%; P = 0.002). Individuals with this genotype had a significantly increased risk for disease. Our results suggest, for the first time, that the homozygous 104NN polymorphism, even at low frequency, constitutes an important inherited determinant of the disease.
References
Nakamura Y, Yasuoka H, Tsujimoto M, Imabun S, Nakahara M, Nakao K, Nakamura M, Mori I, Kakudo K (2005) Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancer. Breast Cancer Res Treat 91(2):125–132
Kuroi K, Tanaka C, Toi M (2001) Circulating levels of endostatin in cancer patients. Oncol Rep 8(2):405–409
Teh SH, Hill AD, Lee AW, Foley D, Kennedy S, Young L, McDermott E, O’Higgins N (2004) Raised plasma endostatin levels correlate inversely with breast cancer angiogenesis. J Surg Res 116(1):165–171
Zhao J, Yan F, Ju H, Tang J, Qin J (2004) Correlation between serum vascular endothelial growth factor and endostatin levels in patients with breast cancer. Cancer Lett 204:87–95
O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277–285
Hampl M, Tanaka T, Albert PS, Lee J, Ferrari N, Fine HA (2001) Therapeutic effects of viral vector-mediated antiangiogenic gene transfer in malignant ascites. Heman Gene Ther 12(14):1713–1729
Indraccolo S, Gola E, Rosato A, Minuzzo S, Habeler W, Tisato V, Roni V, Esposito G, Morini M, Albini A, Noonan DM, Ferrantini M, Amadori A, Chieco-Bianchi L (2002) Differential effects of angiostatin, endostatin and interferon-alpha(1) gene transfer on in vivo growth of human breast cancer cells. Gene Ther 9(13):867–878
Cho HM, Rosenblatt JD, Kang YS, Iruela-Arispe ML, Morrison SL, Penichet ML, Kwon YG, Kim TW, Webster KA, Nechustan H, Shin SU (2005) Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein. Mol Cancer Ther 4(6):956–967
Hasle H, Clemmensen IH, Mikkelsen M (2000) Risks of leukaemia and solid tumours in individuals with Down’s syndrome. Lancet 355:165–169
Iughetti P, Suzuki O, Godoi PH, Alves VAF, Sertié AL, Zorick T, Soares F, Camargo A, Moreira ES, Di Loreto C, Moreira-Filho CA, Simpson A, Oliva G, Passos-Bueno MR (2001) A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma. Cancer Res 61:7375–7378
Macpherson GR, Singh AS, Bennett CL, Venzon DJ, DJ, Franks ME, Dahut WL, Kantoff PW, Price DK, Figg WD (2004) Genotyping and functional analysis of the D104N variant of human endostatin. Cancer Biol Ther 3(12):1298–1303
Dixelius J, Cross M, Matsumoto T, Sasaki T, Timpl R, Claesson-Welsh I (2002) Endostatin regulates endothelial cell adhesion and ctytoskeletal organization. Cancer Res 62:1944–1947
Sudhakat A, Sugimoto H, Yang C, Lively J, Zeisberg M, Kalluri R (2003) Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1integrins. Proc Natl Acad Sci USA 100:4766–4771
Blackhall FH, Merry CL, Lyon M, Jayson GC, Folkman J, Javaherian K, Gallagher JT (2003) Binding of endostatin to endothelial heparan sulphate shows a differential requirement for specific sulphates. Biochem J 375:131–139
MacDonald NJ, Shivers WY, Narum DL, Plum SM, Wingard JN, Fuhrmann SR, Liang H, Holland-Lin J, Chen DH, Sim BK (2001) Endostatin binds tropomyosin: a potential modulator of the antitumor activity of endostatin. J Biol Chem 276:25190–25196
Chang Z, Choon A, Friedl A (1999) Endostatin binds to blood vessels in situ independent of heparan sulphate and does not compete for fibroblast growth factor-2 binding. Am J Pathol 155:71–76
Kim YM, Hwang S, Pyun BJ, Kim TY, Lee ST, Gho YS, Kwon YG (2002) Endostatin blocks vascular endothelial growth factor-mediated signalling via direct interaction with KDR/Flk-1. J Biol Chem 277:27872–27879
Abdollahi A, Hahnfeldt P, Maercker C, Grone HJ, Debus J, Ansorge W, Folkman J, Hlatky L, Huber PE (2004) Endostatin’s antiangiogenic signalling network. Moll Cell 13:649–663
Acknowledgements
The authors are indebted to Fundação de Apoio à Pesquisa do Estado de São Paulo (FAPESP) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) for financial support, and to Mr. Roberto Zulli for the statistical analysis.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lourenço, G., Cardoso-Filho, C., Gonçales, N.L. et al. A high risk of occurrence of sporadic breast cancer in individuals with the 104NN polymorphism of the COL18A1 gene. Breast Cancer Res Treat 100, 335–338 (2006). https://doi.org/10.1007/s10549-006-9259-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-006-9259-z